# NervGen Pharma Corp

NervGen Pharma Corp is an other.

## Overview

- **Organization type:** other
- **Assets under management:** Undisclosed
- **Website:** https://nervgenpharma.com
- **LinkedIn:** https://www.linkedin.com/company/nervgen

## Regulatory record

- **Reports private funds:** No

## Questions

### What is NervGen Pharma Corp's business model?

NervGen Pharma Corp is a clinical-stage biotechnology company, not an asset manager or family office. It develops therapies for nervous system damage, with a lead candidate NVG-291 targeting spinal cord injury and multiple sclerosis. The firm funds operations through public equity markets and potential licensing deals.

### Does NervGen manage capital for any family or institution?

No. NervGen Pharma Corp is a publicly traded company (TSX: NGEN) focused on drug development. It does not operate as a family office, asset manager, or investment firm. Its shareholders include public market investors, not a single family or external allocators.

### What is NervGen's track record in clinical trials?

NervGen has advanced NVG-291 into Phase 1 clinical trials, with a Phase 1b/2a study in spinal cord injury initiated in 2021. The company has published preclinical data in peer-reviewed journals, but no regulatory approvals have been secured. The firm's pipeline also includes programs in multiple sclerosis and Alzheimer's disease.

### What is NervGen's geographic footprint?

NervGen is headquartered in Vancouver, Canada, with its scientific collaborations spanning North American research centers. The company is listed on the TSX Venture Exchange and does not operate additional investment offices in other regions.

## Related profiles

- [Cohen & Steers Total Return Realty Fund](https://altss.com/profile/cohen-and-steers-total-return-realty-fund-inc)

---

Last updated: 2026-05-30T22:57:35.264Z

Canonical page: https://altss.com/profile/nervgen-pharma-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology